semaglutide cardiovascular outcomes 2025 news today VisualAbstract: and in Obesity without Diabetes Cardiovascular outcomes of semaglutide and

Overall, findings from this study suggest that semaglutide 50 mg leads to a clinically significant decrease in body weight among adults with overweight or obese BMIs and no type 2 diabetes

Many people find immediate relief by being more mindful of what and how much they eat

GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies Many Americans seeking popular weight-loss drugs like Wegovy and Zepbound turn to telehealth companies like Hims & Hers for cheaper, compounded alternatives

Straining more than usual during a bowel movement

Professor Hart has received payment for expert testimony in legal cases for patients with hyperstimulation syndrome

We have to employ lifestyle measures and have them occur in a medical setting with team-based care to have lasting impact." Alexander said that care management can be done in person or via telehealth, depending on patient preferences, the resources available and the reimbursement mechanisms at play